Construction and evaluation of an attenuated vaccine for foot-and-mouth disease: Difficulty adapting the leader proteinase-deleted strategy to the serotype O1 virus

Virus Research

Volumn 55, Issue 1, 1998, Pages 49-60

  Almeida, Márcia R ^a   Rieder, Elizabeth ^a   Chinsangaram, Jarasvech ^a   Ward, Gordon ^a   Beard, Clayton ^a   Grubman, Marvin J ^a   Mason, Peter W ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

Author keywords

FMDV; Leader proteinase; Picornavirus; Vaccine

Indexed keywords

FOOT AND MOUTH DISEASE VACCINE; PROTEINASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SWINE; VIRULENCE;

AMINO ACID SUBSTITUTION; ANIMALS; APHTHOVIRUS; CAPSID; CATTLE; CELL LINE; CRICETINAE; ENDOPEPTIDASES; FOOT-AND-MOUTH DISEASE; GENE DELETION; GENETIC ENGINEERING; IMMUNITY, ACTIVE; INTEGRINS; SEROTYPING; SWINE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES; VIRULENCE;

ANIMALIA; BOVINAE; FOOT-AND-MOUTH DISEASE VIRUS; MIRIDAE; PICORNAVIRIDAE; SUS SCROFA;

EID: 0031835331     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(98)00031-8     Document Type: Article

References (31)

1. Alonso A., Darsie G.C., Teixeira A.C., Reis J.L., Mesquita J.A. Application of monoclonal antibodies to quality control of foot-and-mouth disease vaccines. Vaccine. 12:1994;682-686.
2. Bahnemann H.G. Inactivation of virus antigens for vaccine preparation with particular reference to the application of binary ethyleneimine. Vaccine. 8:1990;75-88.
3. Beck E., Strohmaier K. Subtyping of European foot-and-mouth disease virus strain by nucleotide sequence determination. J. Virol. 61:1987;1621-1629.
4. Brown C.C., Piccone M.E., Mason P.W., McKenna T.S.-C., Grubman M.J. Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in cattle. J. Virol. 70:1996;5638-5641.
5. Chinsangaram, J., Mason, P.W., Grubman, M.J., 1998. Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus. Vaccine (in press).
6. Devaney M.A., Vakharia V.N., Lloyd R.E., Ehrenfeld E., Grubman M.J. Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 component of the cap-binding protein complex. J. Virol. 62:1988;4407-4409.
7. Doel T.R., Baccarini P.J. Thermal stability of foot-and-mouth disease virus. Arch. Virol. 70:1981;21-32.
8. Domingo, E., Mateu, M.G., Martínez, M.A., Dopazo, J., Moya, A., Sobrino, F., 1990. Genetic variability and antigenic diversity of foot-and-mouth disease virus. In: Kurstak, E., Marusyk, R.G., Murphy, F.A., Van Regenmortel, M.H.V. (Eds.), Applied Virology Research, vol. 2, Virus Variability, Epidemiology and Control. Plenum, New York, pp. 233-266.
9. Etchison D., Milburn S.C., Edery I., Sonenberg N., Hershey J.W.B. Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex. J. Biol. Chem. 257:1982;14806-14810.
10. Gorbalenya A.E., Koonin E.V., Lai M.M.-C. Putative papain-related thiol proteases of positive-strand RNA viruses: identification of rubi- and aphthovirus proteases and delineation of a novel conserved domain associated with proteases of rubi-, α-, and coronaviruses. FEBS Lett. 288:1991;201-205.
11. Jackson T., Ellard F.M., Abu Ghazaleh R., Brookes S.M., Blakemore W.E., Corteyn A.H., Stuart D.I., Newman J.W.I., King A.M.Q. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J. Virol. 70:1996;5282-5287.
12. King A.M.Q., Underwood B.O., McCahon D., Newman J.W.I., Brown F. Biochemical identification of viruses causing the 1981 outbreaks of foot-and-mouth disease in the UK. Nature. 293:1981;479-480.
13. Kirchweger R., Ziegler E., Lamphear B.J., Waters D., Liebig H.-D., Sommergruber W., Sobrino F., Hohenadl C., Blass D., Rhoads R.E., Skern T. Foot-and-mouth disease virus leader proteinase: purification of the Lb form and determination of its cleavage site on eIF-4γ J. Virol. 68:1994;5677-5684.
14. Kleina L.G., Grubman M.J. Antiviral effects of a thiol protease inhibitor on foot-and-mouth disease virus. J. Virol. 66:1992;7168-7175.
15. Krebs O., Ahl R., Straub O.C., Marquardt O. Amino acid changes outside the G-H loop of capsid protein VP1 of type O foot-and-mouth disease virus confer resistance to neutralization by antipeptide G-H serum. Vaccine. 11:1992;359-362.
16. Mason P.W., Rieder E., Baxt B. RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement mechanism. Proc. Nat. Acad. Sci. USA. 91:1994;1932-1936.
17. Mason P.W., Piccone M.E., McKenna T.St.-C., Chinsangaram J., Grubman M.J. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology. 227:1997;96-102.
18. Medina M., Domingo E., Brangwyn J.K., Belsham G.J. The two species of the foot-and-mouth disease virus leader protein, expressed individually, exhibit the same activities. Virology. 194:1993;355-359.
19. Murphy, B.M., Chanock, R.M., 1996. Immunization against disease. In: Fields, B.N., Knipe, D.M., Howley, P.H. (Eds), Virology. Lippincott-Raven, Philadelphia, pp. 467-497.
20. 3, as its receptor. J. Virol. 72, 3587-3594.
21. Piccone M.E., Rieder E., Mason P.W., Grubman M.J. The foot-and-mouth disease virus leader proteinase gene is not required for viral replication. J. Virol. 69:1995;5376-5382.
22. Rieder E., Bunch T., Brown F., Mason P.W. Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J. Virol. 67:1993;5139-5145.
23. Rieder E., Baxt B., Lubroth J., Mason P.W. Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV. J. Virol. 68:1994;7092-7098.
24. Rieder E., Baxt B., Mason P.W. Animal derived antigenic variants of foot-and-mouth disease virus type A12 have low affinity for cells in culture. J. Virol. 68:1994;5296-5299.
25. Roberts P.J., Belsham G. Identification of the critical amino acids within the foot-and-mouth disease virus leader protein, a cysteine protease. Virology. 213:1995;140-146.
26. Rueckert, R.R., 1996. Picornaviridae: the viruses and their replication. In: Fields, B.N., Knipe, D.M., Howley P.H. (Eds.), Virology. Lippincott-Raven, Philadelphia, pp. 609-654.
27. Sabin A.B. Present status of attenuated live-virus poliomyelitis vaccine. J. Am. Med. Assoc. 162:1956;1589-1596.
28. Sá-Carvalho D., Rieder E., Baxt B., Rodarte R., Tanuri A., Mason P.W. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J. Virol. 71:1997;5115-5123.
29. Stave J.W., Card J.L., Morgan D.O., Vakharia V.N. Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants. Virology. 162:1988;21-29.
30. Strebel K., Beck E. A second protease of foot-and-mouth disease virus. J. Virol. 58:1986;893-899.
31. Taboga O., Tami C., Carrillo E., Núñez J.I., Rodríguez A., Sáiz J.C., Blanco E., Valero M.-L., Roig X., Camarero J.A., Andreu D., Mateu M.G., Giralt E., Domingo E., Sobrino F., Palma E.L. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J. Virol. 71:1997;2606-2614.